



UNITED STATES PATENT AND TRADEMARK OFFICE

[Signature]
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/937,302

03/27/2002

Stefan Hulsmann

SCHUB 1

8375

23599 7590 03/13/2007
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
2200 CLARENDON BLVD.
SUITE 1400
ARLINGTON, VA 22201

EXAMINER

WEBMAN, EDWARD J

ART UNIT

PAPER NUMBER

1616

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

3 MONTHS

03/13/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

09/937,302

Applicant(s)

HULSMANN ET AL.

Examiner

Edward J. Webman

Art Unit

1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 July 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,4,6-13,15,17,19,20 and 22-32 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 4, 6-13, 15, 17, 19-20, 22-32 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1616

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 4, 6, 10-13, 15, 17, 19-20, 22-32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zettler et al in view of Budavari et al.

Zettler et al teach solid dosage forms comprising a drug made by extrusion (abstract). Polyvinylpyrrolidone is disclosed as a binder (column 3 line 48). Triglycerides are specified (column 4 lines 44-47). Estradiol and ethinylestradiol is disclosed (column 6 line 2). 0.1-95% active is specified (column 5 lines 25-26). Tablets are disclosed (column 8 line 64).

Budavari et al teach that desogestrel is used with estrogens in oral contraceptives.

It would have been obvious to one of ordinary skill to add desogestrel in the composition of Zettler et al to achieve the beneficial effect of an oral contraceptive. As to the claimed extrusion without heat input, Zettler et al teach that heating can be done outside the extruder (column 3 lines 9-12). As to the claimed grinding, such would be an obvious expedient to make a granulate for tablets or capsules.

Applicants continues to argue hindsight reconstruction, however, Zettler et al teach applicants' three classes of ingredients (compare applicants' active, extrusion additive, and adjuvant to Zettler et al's pharmaceutical active, flow promoter, and binder/plasticizer).

Applicants argue picking and choosing, however, as asserted previously, Zettler et al disclose that, for the purposes of their invention, the particular species are equivalent. Applicants argue

Art Unit: 1616

that there is no motivation to combine the teachings scattered in Zettler et al. However, those teachings represent the entirety of the Zettler et al disclosure.

Claims 1, 4, 6, 8, 13, 17, 19-20, 22-24, 26-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rosenberg et al.

Rosenberg et al teach a melt-extruded drug form (abstract). Good thermoplasticity is specified (column 1 line 56). Glycerol tribehenate (column 2 line 23) and polyvinylpyrrolidone (column 2 line 26) are disclosed. Any drug under the conditions of melt extrusion is specified (column 2 lines 49-50). Extrusion at 50 degrees Centigrade is disclosed (column 2 line 63). Tablets are specified (column 3 line 3).

The examiner takes notice under MPEP 2144.03 that estradiol has a melting point of 173-179 degrees Centigrade.

It would have been obvious to one of ordinary skill in the art to deliver estradiol in the vehicle of Rosenberg et al to achieve the beneficial effect of a vehicle with good thermoplasticity and in view of the fact that the melting point of estradiol is such that it will not decompose under the conditions of extrusion Rosenberg et al specify.

Applicants argue that Rosenberg et al do not teach applicants' claimed ingredients. However, motivation to add those ingredients is provided.

Claims 1, 4, 6-7, 9-13, 15, 17, 19-20, 22-24, 26-32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Appel et al.

Art Unit: 1616

Appel et al teach a controlled release dosage form (abstract). Polyvinylpyrrolidone is disclosed (column 9 line 4). Saccharose monopalmitate is specified (column 12 line 13, see also column 15 line 64). Tablets are disclosed (column 3 line 25). Low-solubility drugs are specified (column 6 line 5 et seq.).

The examiner takes notice under MPEP 2144.03 that estradiol is almost insoluble in water.

It would have been obvious to one of ordinary skill in the art to achieve deliver estradiol in the vehicle of Appel et al to achieve the beneficial effect of controlled delivery and in view of the fact that the solubility of estradiol is such that it meets the design criteria for the vehicle. Applicants argue that the obvious composition has not been extruded. However, extrusion is disclosed (column 9 lines 11-15).

Applicants appear to have inadvertently overlooked the following 112 rejection in the action filed 7/19/06, repeated below:

Claims 1, 4, 6-13, 15, 17, 19, 22, 24, 26-29 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claims 1 and 26 “obtainable” is vague; it is unclear as to whether what follows is definitely claimed. See claim 20. In claim 28 “an polyvinylpyrrolidone” is indefinite. Is “a” intended? Claims 28-29 do not end with a period.

Claims 1, 4, 6-13, 15, 17, 19-20, 22-32 are rejected.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Edward J. Webman whose telephone number is 571-272-0633. The examiner can normally be reached on M-F from 8 AM to 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, J. Richter, can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Art Unit: 1616

system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



EDWARD J. WEBMAN
PRIMARY EXAMINER
GROUP 1500